Homoharringtonine Rapidly Clears SARS-CoV-2 in URT Models

Study Background and Research Question

The global impact of COVID-19, caused by the third major coronavirus epidemic of this century, has underscored the urgent need for broad-spectrum antivirals that can be deployed quickly at the onset of future outbreaks. Homoharringtonine, a cytotoxic alkaloid traditionally utilized in leukemia and cancer biology research due to its ability to inhibit protein synthesis via binding to the eukaryotic 80S ribosome, has recently emerged as a candidate for antiviral intervention. The central research question addressed in the reference study was whether homoharringtonine could serve as a rapid, scalable means of clearing SARS-CoV-2 from the upper respiratory tract (URT), the primary site of early viral replication and transmission.

Key Innovation from the Reference Study

The principal innovation of the study lies in repurposing homoharringtonine, a molecule with a well-characterized mechanism in cancer biology, for antiviral application against coronaviruses. Unlike conventional antivirals that target viral proteins, homoharringtonine acts as a host-directed agent, blocking protein chain elongation and thereby inhibiting viral replication at the translation level. The study demonstrates that homoharringtonine can suppress SARS-CoV-2 and related coronaviruses at nanomolar concentrations, supporting its role as a broad-spectrum antiviral and establishing a foundation for first-line defense strategies in potential future epidemics.

Methods and Experimental Design Insights

The research combined in vitro, animal model, and early-phase clinical approaches to evaluate the antiviral efficacy of homoharringtonine. In vitro assays tested the compound's effects on viral replication across four different coronaviruses, including SARS-CoV-2, at varying concentrations. In vivo, mice received daily nasal administration of homoharringtonine at a low dose (40 μg), with viral loads monitored in the URT. Further, two small-scale clinical cohorts were included: one involving 26 cancer patients receiving nebulized homoharringtonine (1 mg/day), and another with 11 otherwise healthy individuals administered repeated nasal spray (0.2 mg daily total) during an Omicron surge. Viral clearance was assessed using quantitative PCR, and adverse events were monitored throughout.

Protocol Parameters

• In vitro antiviral testing: Homoharringtonine applied at nanomolar concentrations; specific effective doses determined by cell type and viral strain.
• Animal model administration: Daily nasal dripping of 40 μg homoharringtonine for up to 3 days post-infection in mice.
• Clinical cohort (cancer patients): Nebulization at 1 mg/day, with viral load reassessment at 6 hours post-administration.
• Clinical cohort (healthy individuals): Repeated liquid nasal spray with total daily dose of 0.2 mg; viral clearance monitored over 2–4 days.

Core Findings and Why They Matter

The reference study found that homoharringtonine potently inhibits the replication of SARS-CoV-2 and related coronaviruses in vitro at nanomolar doses. In the animal model, all treated mice cleared the virus from the URT within three days. In the clinical context, cancer patients experienced an average three-quarters reduction in URT viral load within six hours of nebulized treatment. Among healthy individuals treated with nasal spray during an Omicron wave, 10 out of 11 were cleared of the virus within 2–4 days—a substantially faster turnaround than the typical 7–9 days observed in broader population studies during the same period. Notably, no adverse effects were reported in any treated cohort.

These outcomes suggest that homoharringtonine, by targeting host protein synthesis machinery, may circumvent the resistance mechanisms that often limit the efficacy of direct-acting antivirals. Its rapid action and suitability for local delivery (e.g., nasal spray) enable scalable intervention during early infection stages, potentially reducing both disease progression and onward transmission.

Comparison with Existing Internal Articles

Several recent reviews and analysis pieces reinforce and contextualize the findings of the reference study. For instance, Homoharringtonine Rapidly Clears SARS-CoV-2: Molecular Insights provides an in-depth discussion of the molecular mechanisms and highlights the compound’s versatility in both cancer and antiviral research. Similarly, Homoharringtonine: Cytotoxic Alkaloid for Cancer and Antiviral Research details its dual activity profile, noting the mechanistic link between protein synthesis inhibition in leukemic cells and suppression of viral replication. The article Bridging Leukemia Research and Coronavirus Defense uniquely explores the translational implications of homoharringtonine across domains, affirming that its established protocols in leukemia research can inform antiviral workflow optimization. These resources collectively support the emerging consensus that homoharringtonine’s cytotoxic and protein synthesis-inhibiting properties provide a mechanistic basis for cross-domain applications.

Limitations and Transferability

While the study provides compelling preclinical and early clinical evidence, several limitations warrant consideration. The clinical sample sizes were small, and the patient populations—particularly cancer patients—may not reflect broader demographic or comorbidity profiles. Although no adverse effects were observed, longer-term safety data are needed, especially with repeated or higher-dose exposure. The transferability of dosing regimens from controlled models to real-world, large-scale settings remains to be validated. Additionally, while homoharringtonine’s host-directed mechanism may reduce the risk of viral resistance, it raises questions about potential impacts on host cell function, particularly with chronic or high-dose use. Direct comparative trials with other antiviral agents are also necessary to delineate relative efficacy and safety profiles.

Why this cross-domain matters, maturity, and limitations

The repurposing of homoharringtonine from cancer biology and leukemia research to SARS-CoV-2 antiviral strategies exemplifies the value of cross-domain translational science. Established knowledge around cell cycle G1 phase arrest and protein synthesis inhibition in leukemic cells has facilitated rapid protocol adaptation for antiviral workflows, as discussed in the internal review Homoharringtonine: Cytotoxic Alkaloid for Cancer and SARS-CoV-2. However, despite promising early-phase results, homoharringtonine’s use as a first-line antiviral remains investigational. The maturity of evidence is strongest in preclinical and case-series contexts; further randomized, controlled trials will be essential for regulatory consideration and broad clinical adoption.

Research Support Resources

For researchers seeking to replicate or extend these findings, Homoharringtonine (SKU N1504) is available as a research-use-only cytotoxic alkaloid. According to the product information, it is suitable for advanced cancer biology and SARS-CoV-2 antiviral research workflows, with established solubility and storage protocols. Its use should remain confined to controlled laboratory settings, and all applicable biosafety and cytotoxic handling guidelines must be observed.